History

1. 2023

   1. Exclusive License Agreement with TB Alliance to develop and commercialize Telacebec(Q203)

      02.03

   2. Designated as “Korea Innovative Pharmaceutical Company” (Ministry of Health and Welfare)

      01.19

2. 2022

   1. Collaboration Agreement with MSD to Evaluate Selective CDK7 Inhibitor Q901 in Combination With KEYTRUDA®

      09.14

   2. MFDS approval for Q702 phase 1b/2 study in Combination With KEYTRUDA®

      09.06

   3. US FDA IND filing for Q702 phase 1b/2 study in Combination With KEYTRUDA®

      02.16

   4. Telacebec(Q203), voluntarily suspend of COVID-19 phase 2 study in public of South Africa

      02.11

   5. Q901, US FDA approval for phase 1/2 study

      02.08

3. 2021

   1. Capital raise of 5 million EUR in QLi5 Therapeutics(Subsidiary)

      12.22

   2. Capital raise of 12.5 billion KRW

      12.17

   3. Collaboration Agreement with MSD to Evaluate Selective Triple Inhibitor Q702 in Combination With KEYTRUDA®

      11.23

   4. Q702, Presented by SWOG(Southwest Oncology Group) Fall 2021 Meeting

      10.14

   5. Posted 2021 AACR annual meeting(Q901)

      04.12

   6. Q702, Initiation of clinical patient dosing for phase 1/2 study in US

      01.26

   7. FDA grants orphan drug designation to Qurient’s Buruli ulcer treatment(Telacebec)

      01.14

4. 2020

   1. Telacebec(Q203), approval for COVID-19 phase 2 study in Republic of South Africa

      11.24

   2. Capital raise of 60 billion KRW

      10.29

   3. Telacebec(Q203), IND filing of COVID-19 phase 2 study in Republic of South Africa

      10.13

   4. Telacebec(Q203), Signed a Material Transfer Agreement with Janssen

      09.24

   5. Posted 2020 AACR annual meeting (Q702 / Q901)

      06.23

   6. Q301, Completion of phase 2b study

      05.28

   7. Q702, US FDA approval for Immuno-oncology therapy phase 1 study

      05.23

   8. Published in New England Journal of Medicine(NEJM) to result of Telacebec(Q203) phase 2a study

      03.26

   9. Establishment of subsidiary "QLi5 Therapeutics GmbH" in Germany

      01.16

5. 2019

   1. Telacebec(Q203), Completion of Tuberculosis phase 2a study

      12.17

   2. Posted 2019 AACR annual meeting in Atlanta (Q702)

      04.02

   3. Q301 Phase 2a Results presented at 2019 American Academy of Dermatology Annual Meeting in Washington DC

      03.02

6. 2018

   1. Telacebec (Q203) U.S. FDA Fast Track Designation

      11.12

   2. Capital raise of 40 billion KRW

      10.19

   3. Received grant from Korea Drug Development Fund for Telacebec (Q203) Phase 2a study

      10.01

   4. US FDA approval for Telacebec (Q203) phase 2a study

      07.16

   5. US FDA approval for Q301 phase 2b study

      06.21

   6. Completion of TB Telacebec (Q203) phase 1b study

      05.05

   7. Confirmation of “Telacebec ” as a generic name for Q203 by INN & USAN

      03.01

7. 2017

   1. South Africa MCC approval for Q203 phase 2a study

      12.20

   2. Posted 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Q701 & Q702 / Q901 )

      10.26

   3. Published in European Journal of Medicinal Chemistry. 136 (2017);420-427 (Title : Synthesis and structure-activity relationships of novel fused ring analogues of Q203 as antitubercular agents)

      08.18

   4. EDCTP(European & Developing Countries Clinical Trials Partnership) grant awarded to PanACEA consortium to run Q203 clinical studies

      02.28

   5. Published in European Journal of Medicinal Chemistry. 125 (2017);807-815 (Title : Synthesis and structure-activity studies of side chain analogues of the anti-tubercular agent, Q203)

      01.05

8. 2016

   1. US FDA approval for Q203 Phase 1b study

      08.29

   2. Completion of Q301 phase 2a study

      05.19

   3. Initial public offering on Korea Exchange (KRX:115180)

      02.29

9. 2015

   1. Q203 U.S. FDA Orphan Drug Designation

      12.28

   2. Received grant from Korea Drug Development Fund for Q203 phase 1 study

      12.16

   3. US FDA IND approval for Q203 phase 1 study

      07.23

   4. US FDA approval for Q301 phase 2a study

      03.12

   5. In-licensed CDK7 inhibitor program from Max Planck Innovation / Lead Discovery Center

      02.27

   6. Umbrella partnership agreement signed with Max Planck Innovation / Lead Discovery Center

      02.06

10. 2014

    1. Capital raise of 15.5 billion KRW

       06.09

    2. Published in Journal of Medicinal Chemistry. 57(12);5293–5305 (Title : Lead Optimization of a Novel Series of Imidazo[1,2-a]pyridine Amides Leading to a Clinical Candidate (Q203) as a Multi- and Extensively-Drug-Resistant Anti-tuberculosis Agent)

       05.28

    3. Russia and CIS rights for Q203 licensed to Infectex (a subsidiary company of Maxwell Biotech Group, Russia)

       01.21

11. 2013

    1. Published in Nature medicine. 19(9);1157-60. (Title : Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis)

       08.04

    2. Capital raise of 3 billion KRW

       05.10

    3. Received grant from Korea Drug Development Fund for Q203 preclinical IND enabling studies

       04.30

    4. In-licensed Axl inhibitor program from Max Planck Innovation / Lead Discovery Center

       02.21

12. 2012

    1. Capital raise of 3 billion KRW

       09.19

13. 2011

    1. Company name change to “Qurient Co., Ltd”

       10.21

    2. Capital raise of 1 million USD

       02.09

14. 2010

    1. Won Gate II competition for 1M USD investment by Novartis Venture Fund

       09.02

    2. In-licensed anti-tuberculosis antibiotics programs from Institut Pasteur Korea

       03.04

15. 2009

    1. Series A finance of 4 billion KRW

       11.20

16. 2008

    1. Foundation of Qurient (formerly Quro Science Co. Ltd.)

       07.02